Bipolar Disorder and Safety Monitoring for Clinicians: A Review of the Evidence and the Implications

Bipolar Disorder: Clinical and Neurobiological Foundations

Volumn , Issue , 2010, Pages 367-383

  Bushe, Chris J ^a   Tohen, Mauricio ^b  

^a Lilly UK   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adverse events, associated with lithium treatment and toxicity; Bipolar disorder and safety monitoring for clinicians review of evidence and implications; Bipolar disorder, complex disorder moving through phases in patients; Generic bipolar safety monitoring; Lamotrigine, carbamazepine and valproate and mucocutaneous syndromes; Lithium, dosing and toxicity effective treatment in bipolar disorder associated with adverse events; Metabolic abnormalities, highest in schizoaffective patients; Metabolic syndrome, entity not graded no means of assessing worsening symptoms; Metabolism and bipolar disorder metabolic issues in bipolar disorder; Severe mental illness (SMI)

Indexed keywords

EID: 84859820264     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470661277.ch28     Document Type: Chapter

References (104)

1. van Winkel, R., De Hert, M., Van Eyck, D. et al. (2008) Peuskens. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. J. Bipolar Disord., 10 (2), 342.
2. National Institute for Health, Clinical Excellence (NICE) (2006) Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline 38 [cited 2009 March 14]; Available from: www.nice.org.uk/CG038.
3. American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry, 159, 1-50.
4. Yatham, L.N., Kennedy, S.H., O'Donovan, C. et al. 2006. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord., 8, 721-739.
5. Guideline on risk management systems for medicinal products for human use. CHMP. http://www.emea.europa.eu/pdfs/human/euleg/9626805en.pdf (accessed 19 July 2009).
6. Dalton, S.O., Mellemkjaer, L., Thomassen, L. et al. (2005) Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr. Res., 75 (2-3), 315-324.
7. Smith, S., Yeomans, D., Bushe, C.J. et al. (2007) A well-being programme in severe mental illness. Baseline findings in a UK cohort. Int. J. Clin. Pract., 61 (12), 1971-1978.
8. McEvoy, J., Meyer, M., Goff, D. et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res., 80, 19-32.
9. Smith, S., Yeomans, D., Bushe, C.J. et al. (2007) A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years. Eur. Psychiatry, 22, 413-418.
10. Fagiolini, A., Frank, E., Scott, J.A. et al. (2005) Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord., 7 (5), 424-430.
11. Bushe, C. (2009) Glucose abnormalities in Schizophrenia, Bipolar and Major Depressive disorders, in Metabolic Effects of Psychotropic Drugs, 26 (eds J. Thakore and B.E. Leonard), Karger, pp. 47-65.
12. Bushe, C.J. and Leonard, B.E. (2007) Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J. Clin. Psychiatry, 68, 1682-1690.
13. Vemuri, M., Stemmle, P., Jiang, B. et al. (2009) Insulin resistance in bipolar women; effects of mood-stabilising drugs, in Metabolic Effects of Psychotropic Drugs, 26 (eds J. Thakore B.E., Leonard), Karger, pp. 12-24.
14. Susce, M.T., Villanueva, N., Diaz, F.J. et al. (2005) Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J. Clin. Psychiatry, 66 (2), 167-173.
15. Regenold, W.T., Thapar, R.K., Marano, C. et al. (2002) J Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. Affect. Disord., 70 (1), 19-26; Erratum in: J Affect Disord. 2003; Feb 73 (3) 301-302.
16. Bushe, C. and Leonard, B. (2004) Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br. J. Psychiatry, 47 (Suppl.), S87-S93.
17. Ormerod, S., McDowell, S.E., Coleman, J.J. and Ferner, R.E. (2008) Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf., 31 (7), 597-607.
18. Wang, P.W., Sachs, G.S., Zarate, C.A. et al. (2006) Overweight and obesity in bipolar disorders. J. Psychiatr. Res., 40 (8), 762-764.
19. Garcia-Portilla, M.P., Saiz, P.A., Benabarre, A. et al. (2008) The prevalence of metabolic syndrome in patients with bipolar disorder. Affect. Disord., 106 (1-2), 197-201.
20. Yumru, M., Savas, H.A., Kurt, E. et al. (2007) Atypical antipsychotics related metabolic syndrome in bipolar patients. J. Affect. Disord., 98 (3), 247-252.
21. Paton, C., Esop, R., Young, C. and Taylor, D. (2004) Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr. Scand., 110, 299-305.
22. Barnes, T.R., Paton, C., Cavanagh, M.R. et al. (2007) UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr. Bull., 33 (6), 1397-1403.
23. National Institute for Health, Clinical Excellence (2008) Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. NICE Clinical Guideline 67, National Institute for Health and Clinical Excellence, London.
24. Bauer, M., Lecrubier, Y. and Suppes, T. (2008) Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists. Eur. Psychiatry, 23 (3), 169-177.
25. Bendz, H., Aurell, M., Balldin, J. et al. (1994) Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol. Dial Transplant, 9, 1250-1254.
26. Boton, R., Gaviria, M. and Batlle, D.C. (1987) Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am. J. Kidney Dis., 10, 329-345.
27. Thompson, C.J., France, A.J. and Baylis, P.H. (1997) Persistent nephrogenic diabetes insipidus following lithium therapy. Scott. Med. J., 42, 16-17.
28. Vanderpump, M.P., Tunbridge, W.M., French, J.M. et al. (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.), 43, 55-68.
29. Johnston, A.M. and Eagles, J.M. (1999) Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br. J. Psychiatry, 175, 336-339.
30. Bendz, H., Sjodin, I., Toss, G. and Berglund, K. (1996) Hyperparathyroidism and long-term lithium therapy-a cross-sectional study and the effect of lithium withdrawal. J. Intern. Med., 240, 357-365.
31. Sachs, G., Bowden, C., Calabrese, J.R. et al. (2006) Effects of lamotrigineandlithiumonbodyweightduringmaintenance treatment of bipolar I disorder. Bipolar Disord., 8, 175-181.
32. Tohen, M., Greil, W., Calabrese, J.R. et al. (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry, 162 (7), 1281-1290.
33. Callaghan, N., Majeed, T., O'Connell, A. and Oliveira, D.B. (1994) A comparative study of serum F protein and other liver function tests as an index of hepatocellular damage in epileptic patients. Acta Neurol. Scand., 89, 237-241.
34. Wolf, R., Matz, H., Marcos, B. and Orion, E. (2005) Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification. Clin. Dermatol., 23, 311-314.
35. Dong, X., Leppik, I.E., White, J. and Rarick, J. (2005) Hyponatremia from oxcarbazepine and carbamazepine. Neurology, 65, 1976-1978.
36. Tohen, M., Castillo, J., Baldessarini, R.J. et al. (1995) Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am. J. Psychiatry, 152, 413-418.
37. Powell-Jackson, P.R., Tredger, J.M. and Williams, R. (1984) Hepatotoxicity to sodium valproate: a review. Gut., 25, 673-681.
38. Petty, S.J., O'Brien, T.J. and Wark, J.D. (2007) Anti-epileptic medication and bone health. Osteoporos Int., 18, 129-142.
39. Bowden, C.L., Calabrese, J.R., McElroy, S.L. et al. (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry, 57, 481-489.
40. Tohen, M., Ketter, T.A., Zarate, C.A. et al. (2003) Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry, 160, 1263-1271.
41. Joffe, H., Cohen, L.S., Suppes, T. et al. (2006) Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol. Psychiatry, 59 (11), 1078-1086.
42. O'Donovan, C., Kusumakar, V., Graves, G.R. and Bird, D.C. (2002) Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J. Clin. Psychiatry, 63 (4), 322-330.
43. Calabrese, J.R., Sullivan, J.R., Bowden, C.L. et al. (2002) Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J. Clin. Psychiatry, 63, 1012-1019.
44. Bowden, C.L., Asnis, G.M., Ginsberg, L.D. et al. (2004) Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf., 27, 173-218.
45. Guberman, A.H., Besag, F.M., Brodie, M.J. et al. (1999) Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia, 40, 985-991.
46. Mockenhaupt, M., Messenheimer, J., Tennis, P. and Schlingmann, J. (2005) Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology, 64, 1134-1138.
47. Ketter, T.A., Brooks, J.O., Hoblyn, J.C. et al. (2008) Effectiveness of lamotrigine in bipolar disorder in a clinical setting. J. Psychiatr. Res., 43 (1), 13-23.
48. L'Italien, G.J., Casey, D.E., Kan, H.J. et al. (2007) Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J. Clin. Psychiatry, 68 (10), 1510-1516.
49. Tohen, M., Sutton, V.K., Calabrese, J.R. et al. (2009) Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J. Affect. Disord., 116 (1-2), 43-50.
50. Kahn, R.S., Fleischhacker, W.W., Boter, H. et al. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, 371, 1085-1097.
51. Lieberman, J.A., Stroup, T.S., McEvoy, J.P. et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 353 (12), 1209-1223.
52. Bushe, C., Sniadecki, J., Bradley, A. and Poole Hoffmann, V. (2009) Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J. Psychopharmacol., Feb 24. [Epub ahead of print]. PMID: 19240085.
53. Tohen, M. et al. (2006) Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine.
54. Niufan, G., Tohen, M., Qiuqing, A. et al. (2008) Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J. Affect. Disord., 105 (1-3), 101-108.
55. Tohen, M. et al. (2000) Efficacy of olanzapine in acute bipolar mania. a double blind placebo controlled study. Arch. Gen. Psychiatry, 57, 841-849.
56. Hennen, J., Perlis, R.H., Sachs, G. et al. (2004) Weight gain during treatment of bipolar I patients with olanzapine. J. Clin. Psychiatry, 65 (12), 1679-1687.
57. Schneeweiss, S. and Avorn, J. (2009) Antipsychotic agents and sudden cardiac death--how shouldwemanage the risk? N. Engl. J. Med., 360 (3), 294-296.
58. Bowden, C.L. et al. (2005) A Randomised, double blind, placebo controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry, 66, 111-121.
59. McIntyre, R.S. et al. (2005) Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double blind, randomised, parallel group, placebo controlled trial. Eur. Neuropsychopharmacol., 15, 573-585.
60. Vieta, E. et al. (2005) Effectiveness of aripiprazole versus haloperidol in acute bipolar mania. Double blind, randomised, comparative 12 week trial. B. J. Psych., 187, 235-242.
61. Keck, P.E. et al. (2009) Aripiprazole monotherapy in the treatment of acute bipolar i mania: a randomized, doubleblind, placebo and lithium controlled study. J. Affect. Disord., 112 (1-3), 36-49.
62. Thase, M.E. et al. (2008) Aripiprazole monotherapy in nonpsychotic bipolar I depression results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol., 28, 13-20.
63. Smulevich, A.B. et al. (2005) Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebocontrolled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur. Neuropsychopharmacol., 15, 75-84.
64. Neovius, M., Eberhard, J., Lindström, E. and Levander, S. (2007) Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr. Scand., 115 (4), 277-285.
65. Bushe, C.J. and Leonard, B.E. (2007) Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J. Clin. Psychiatry, 68 (11), 1682-1690.
66. Meyer, J.M., Davis, V.G., Goff, D.C. et al. (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr. Res., 101, 273-286.
67. Stroup, T.S., Lieberman, J.A., McEvoy, J.P. et al. (2009) CATIE Investigators Results of phase 3 of the CATIE schizophrenia trial. Schizophr. Res., 107 (1), 1-12.
68. McEvoy, J.P., Lieberman, J.A., Perkins, D.O. et al. (2007) Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of early psychosis:Arandomised, double blind 52 week comparison. Am. J. Psychiatry, 164, 1050-1060.
69. Clinical study D144CC00004 (Nov 2007) A Multicenter, Double-blind, Randomized, Parallel-group, Placebo controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-release as Monotherapy in Adult Patients with Acute Bipolar Mania.
70. Strom, B., Faich, G., Eng, S. et al. (2008) Comparative moratility associated with ziprasidone vs olanzapine in real-world use: the ziprasidone observational study of cardiac outcomes (ZODIAC). Schizophr. Res., 98, 160-161. doi: 10.1016/j.schres.2007.12.377
71. Bushe, C. and Paton, C. (2005) The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J. Psychopharmacol., 19 (6 Suppl), 76-83.
72. Taylor, D., Young, C., Esop, R. et al. (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br. J. Psychiatry, 185, 152-156.
73. Olfson, M., Marcus, S.C., Corey-Lisle, P. et al. (2006) Hyperlipidemia following treatment with antipsychotic medications. Am. J. Psychiatry, 163 (10), 1821-1825.
74. Keck, P.E. et al. (2006) A randomised double blind placebo controlled 26 week trial of aripiprazole in recently manic patients with bipolar 1 disorder. J. Clin. Psychiatry, 67, 626-637.
75. Keck, P.E. et al. (2007) Aripiprazole monotherapy for maintenance treatment in bipolar disorder: a 100 week double blind study versus placebo. J. Clin. Psychiatry, 68, 1480-1491.
76. Daumit, G.L., Goff, D.C., Meyer, J.M. et al. (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr. Res., 105, 175-187.
77. Hippisley-Cox, J., Vinogradova, Y., Coupland, C. and Parker, C. (2007) Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch. Gen. Psychiatry, 64 (12), 1368-1376.
78. Werneke, U., Horn, O., Maryon-Davis, A. et al. (2006) Uptake of screening for breast cancer in patients with mental health problems. J. Epidemiol. Community Health, 60 (7), 600-605.
79. Bushe, C., Shaw, M. and Peveler, R. (2008) A review of the association between antipsychotics and hyperprolactinaemia. J. Psychopharm., 22 (2 Suppl), 46-55.
80. Turrone, P., Kapur, S., Seeman, M.V. and Flint, A.J. (2002) Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry, 159 (1), 133-135.
81. Bushe, C. and Shaw, M. (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J. Psychopharmacol., 21 (7), 768-773.
82. Johnsen, E., Kroken, R.A., Abaza, M. et al. (2008) Antipsychotic- induced hyperprolactinemia: a cross-sectional survey. J. Clin. Psychopharmacol., 28 (6), 686-690.
83. Tworoger, S.S. and Hankinson, S.E. (2006) Prolactin and breast cancer risk. Cancer Lett., 243, 160-169.
84. Catts, V.S., Catts, S.V., O'Toole, B.I. and Frost, A.D. (2008) Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr. Scand., 117 (5), 323-336.
85. Harrigan, E.P., Miceli, J.J., Anziano, R. et al. (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol., 24 (1), 62-69.
86. Ray, W.A., Chung, C.P., Murray, K.T. et al. (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med., 360 (3), 225-235.
87. Schneeweiss, S. and Avorn, J. (2009) Antipsychotic agents and sudden cardiac death--how shouldwemanage the risk? N. Engl. J. Med., 360 (3), 294-296.
88. Seeman, M.V. (2008) Prevention inherent in services for womenwithschizophrenia. Can.J. Psychiatry,53(5),332-341.
89. Bushe, C., O'Neil, J., Wood, C. et al. (2007) Physical health monitoring in a scottish cohort of schizophrenia patients - The role of ECG & blood pressure monitoring. Presented at 62nd Annual Convention of the Society of Biological Psychiatry. San Diego May 2007.
90. Justo, D., Prokhorov, V., Heller, K. and Zeltser, D. (2005) Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr. Scand., 111 (3), 171-176.
91. Cole, D.P., Thase, M.E., Mallinger, A.G. et al. (2002) Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am. J. Psychiatry, 159, 116-121.
92. Fagioline, A., Kupfer, D.J., Scott, J. et al. (2006) Hypothyroidism in patients with bipolar 1 disorder treated primarily with lithium. Epidemiol. Psychiatr. Soc., 15, 123-127.
93. Gough, S. and Peveler, R. (2004) Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br. J. Psychiatry, 47 (Suppl.), S106-S111.
94. Nordestgaard, B.G., Benn, M., Schnohr, P. and Tybjaerg- Hansen, A. (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 298 (3), 299-308.
95. Bansal, S., Buring, J.E., Rifai, N. et al. (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 298 (3), 309-316.
96. Holt, R.I.G. (2009) Screening for diabetes and cardiovascular risk factors in people with serious mental illness, in Metabolic Effects of Psychotropic Drugs, 26 (eds J. Thakore and B.E. Leonard), Karger, pp. 66-81.
97. Hanssens, L., De Hert, M., Kalnicka, D. et al. (2007) Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int. Clin. Psychopharmacol., 22 (1), 43-49.
98. Barnes, T.R., Paton, C., Hancock, E. et al. (2008) UK prescribing observatory for mental health. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr. Scand., 118 (1), 26-33.
99. Pendlebury, J., Bushe, C.J., Wildgust, H.J. and Holt, R.I. (2007) Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr. Scand., 115 (4), 286-294.
100. Poole Hoffmann, V., Bushe, C., Meyers, A.L. et al. (2008) A wellness intervention program for patients with mental illness: self-reported outcomes. Prim Care Companion J. Clin. Psychiatry, 10 (4), 329-331.
101. Menza, M., Vreeland, B., Minsky, S. et al. (2004) Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J. Clin. Psychiatry, 65, 471-477.
102. Mauri, M., Castrogiovanni, S., Simoncini, M. et al. (2006) Effects of an educational intervention on weight gain in patients treated with antipsychotics. J. Clin. Psychopharmacol., 26 (5), 462-466.
103. Bushe, C.J., McNamara, D., Haley, C. et al. (2008) Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. Apreliminary service evaluation. BMC Psychiatry, 8, 76.
104. Peveler, R.C., Branford, D., Citrome, L. et al. (2008) Antipsychotics and hyperprolactinaemia: clinical recommendations. J. Psychopharmacol., 22 (2 Suppl), 98-103.